Ischemic Heart Disease pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 176 pages | ID: ICCF467BD9D3EN
VPAResearch

Abstracts

2020 Ischemic Heart Disease PIPELINE HIGHLIGHTS
Ischemic Heart Disease is one of the widely researched conditions during 2020 with 39 companies actively focusing on realizing pipeline’s potential. Development of Ischemic Heart Disease medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Ischemic Heart Disease market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Ischemic Heart Disease.

Good progress is anticipated during 2020 and 2021 with Ischemic Heart Disease pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Ischemic Heart Disease pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Ischemic Heart Disease DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Ischemic Heart Disease pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Ischemic Heart Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Ischemic Heart Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Ischemic Heart Disease pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Ischemic Heart Disease DRUG PROFILES
Ischemic Heart Disease development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Ischemic Heart Disease COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Ischemic Heart Disease drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Ischemic Heart Disease. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 39 Ischemic Heart Disease companies including company overview, key snapshot, contact information, and their strategies on accelerating Ischemic Heart Disease pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- advanceCor GmbH, AgeX Therapeutics Inc, AngioSoma Inc, Ascendia Pharmaceuticals LLC, AstraZeneca Plc, Athera Biotechnologies AB, Bayer HealthCare Pharmaceuticals, Bio-Thera Solutions Ltd, Cadrock Pty Ltd, Capricor Therapeutics Inc, CardioVascular BioTherapeutics Inc, CeleCor Therapeutics Inc, Chong Kun Dang Pharmaceutical Corp, CSL Ltd, Cynata Therapeutics Ltd, DalCor Pharmaceuticals Inc, Diapin Therapeutics LLC, Elevian Inc, Gilead Sciences Inc, Helixmith Co Ltd, Hemostemix Inc, Honya Medical Inc, Idorsia Ltd, Innolife Co Ltd, Jaan Biotherapeutics LLC, LipimetiX Development Inc, MedImmune LLC, Orion Corporation, Pharmahungary Group, Resverlogix Corp, Reven Pharmaceuticals Inc, Theratome Bio Inc, Verseon Corp, Verve Therapeutics Inc, VESSL Therapeutics Ltd, ViroMed Co Ltd, Virtual Drug Development Inc, XyloCor Therapeutics Inc, Zhittya Genesis Medicine Inc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Ischemic Heart Disease
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ISCHEMIC HEART DISEASE

1.1 Ischemic Heart Disease- Disease overview
1.2 Ischemic Heart Disease- Market Size
1.3 Ischemic Heart Disease- Companies Involved

2. ISCHEMIC HEART DISEASE PIPELINE SNAPSHOT- 2020

2.1 Ischemic Heart Disease Pipeline by Phase
2.2 Ischemic Heart Disease Pipeline by Mechanism of Action
2.3 Ischemic Heart Disease Pipeline by Route of Administration
2.4 Ischemic Heart Disease Pipeline- New Molecular Entities
2.5 Ischemic Heart Disease Pipeline- Orphan Drug Designation/ Special Designation

3. ISCHEMIC HEART DISEASE DRUG PROFILES

3.1 Current Status
3.2 Ischemic Heart Disease Drug Snapshot
3.3 Ischemic Heart Disease Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 advanceCor GmbH Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.2 AgeX Therapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.3 AngioSoma Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.4 Ascendia Pharmaceuticals LLC Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.5 AstraZeneca Plc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.6 Athera Biotechnologies AB Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.7 Bayer HealthCare Pharmaceuticals Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.8 Bio-Thera Solutions Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.9 Cadrock Pty Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.10 Capricor Therapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.11 CardioVascular BioTherapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.12 CeleCor Therapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.13 Chong Kun Dang Pharmaceutical Corp Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.14 CSL Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.15 Cynata Therapeutics Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.16 DalCor Pharmaceuticals Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.17 Diapin Therapeutics LLC Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.18 Elevian Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.19 Gilead Sciences Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.20 Helixmith Co Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.21 Hemostemix Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.22 Honya Medical Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.23 Idorsia Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.24 Innolife Co Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.25 Jaan Biotherapeutics LLC Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.26 LipimetiX Development Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.27 MedImmune LLC Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.28 Orion Corporation Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.29 Pharmahungary Group Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.30 Resverlogix Corp Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.31 Reven Pharmaceuticals Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.32 Theratome Bio Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.33 Verseon Corp Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.34 Verve Therapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.35 VESSL Therapeutics Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.36 ViroMed Co Ltd Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.37 Virtual Drug Development Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.38 XyloCor Therapeutics Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials
4.39 Zhittya Genesis Medicine Inc Ischemic Heart Disease Pipeline Insights and Clinical Trials

5. ISCHEMIC HEART DISEASE MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information